Savara (NASDAQ:SVRA) Rating Increased to Buy at HC Wainwright

Savara (NASDAQ:SVRA) was upgraded by analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, MarketBeat reports. The brokerage currently has a $5.00 price objective on the stock, up from their prior price objective of $2.00. HC Wainwright’s price objective would indicate a potential upside of 64.47% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on SVRA. Evercore ISI dropped their price target on Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a research note on Wednesday, May 28th. Wells Fargo & Company dropped their price target on Savara from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 28th. Finally, Guggenheim restated a “buy” rating and issued a $8.00 price target (down previously from $9.00) on shares of Savara in a research note on Wednesday, May 28th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Savara has a consensus rating of “Moderate Buy” and an average target price of $6.17.

Savara Trading Up 1.0%

NASDAQ SVRA opened at $3.04 on Friday. The company has a market cap of $525.43 million, a PE ratio of -6.08 and a beta of 0.40. The company has a current ratio of 11.08, a quick ratio of 14.91 and a debt-to-equity ratio of 0.25. Savara has a 12 month low of $1.89 and a 12 month high of $4.70. The stock has a 50 day moving average of $2.39 and a 200-day moving average of $2.66.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). On average, equities research analysts anticipate that Savara will post -0.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard J. Hawkins purchased 48,225 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The shares were bought at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the transaction, the director owned 115,466 shares of the company’s stock, valued at approximately $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 5.33% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Altium Capital Management LLC increased its position in shares of Savara by 0.3% in the fourth quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company’s stock worth $4,848,000 after purchasing an additional 4,000 shares during the period. BNP Paribas Financial Markets boosted its stake in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Savara by 13.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company’s stock valued at $135,000 after buying an additional 5,236 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Savara by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company’s stock valued at $441,000 after buying an additional 5,450 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in Savara by 17.6% in the second quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock valued at $87,000 after buying an additional 5,687 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.